Abstract
The treatment of medulloblastoma, the most common malignant brain tumor in children, has evolved over the last few decades. The objectives of this paper were to determine the survival of pediatric medulloblastoma in Canada, to determine if there has been an improvement in the survival rates between the years of 1990 and 2009, inclusive, and to determine prognostic factors for survival. All patients under the age of 18 years diagnosed with medulloblastoma from 1990 to 2009, inclusive, in Canada were included. Data collected included date of diagnosis, age at diagnosis, gender, stage, pathology, treatment, recurrence and current status. From these, survival rates were determined. Data were obtained on 628 eligible patients. The overall 5-year survival rate for the study time period was 69.2 ± 3.3 %. The survival rate increased during the interval of 1996–2000, then remained stable; 1990–1994: 60.2 ± 4.3 %; 1995–1999: 73.2 ± 3.5 %; 2000–2004: 68.8 ± 3.7 %; and 2005–2009: 72.1 ± 4.9 %, p = 0.05. Children over 14 years of age had a significantly better overall survival than those age 5–14 and those under 5 (85.7 ± 5.5 % vs 76.1 ± 2.7 % and 60.8 ± 3 % respectively, p = 0.001). Histologic medulloblastoma subtype and M stage of disease did not result in significant differences in survival. Despite changes in approaches to therapy, we demonstrate a steady survival rate for children with medulloblastoma after 1996. In our analyses, age over 14 years was associated with a higher survival rate.
Similar content being viewed by others
References
Packer RJ, Cogen P, Vezina G, Rorke LB (1999) Medulloblastoma: clinical and biological aspects. Neurooncology 1:232–250
Gajjar A, Packer RJ, Foreman NK, Cohen K, Haas-Kogan D, Merchant TE (2013) Children’s Oncology Group 2013 blueprint for research: central nervous system tumors. Pediatr Blood Cancer 60:1022–1026
Smoll NR (2012) Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs). Cancer 118:1313–1322
Patel S, Bhatnagar A, Wear C, Osiro S, Gabriel A, Kimball D, John A, Fields PJ, Tubbs S, Loukas M (2014) Are pediatric brain tumors on the rise in the USA? Significant incidence and survival findings from the SEER database analysis. Childs Nerv Syst 30:147–154
Von Hoff K, Hinkes B, Gerber NU, Deinlein F, Mittler U, Urban C, Benesch M, Warmuth-Metz M, Soerensen N, Zweiner I, Goette H, Schlegel PG, Pietsch T, Kortmann RD, Kuehl J, Rutkowski S (2009) Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomized multicenter trial HIT’91. Eur J Cancer 45:1209–1217
Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, Massimino M, Reddingius R, Benesch M, Carrie C, Taylor R, Gandola L, Bjork-Eriksson T, Giralt J, Olderberger F, Pietsch T, Figarella-Branger D, Robson K, Formi M, Clifford SC, Warmuth-Metz M, von Hoff K, Faldum A, Mosseri V, Kortmann R (2012) Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 30:3187–3193
Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A (2013) Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children’s Oncology Group trial A9961. Neuro-Oncology 15:97–103
Jakacki R, Burger PC, Zhou T, Holmes EJ, Kocak M, Onar A, Goldwein J, Mehta M, Packer RJ, Tarbell N, Fitz C, Vezina G, Hilden J, Pollack IF (2012) Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children’s Oncology Group Phase I/II study. J Clin Oncol 30:2648–2653
Gajjar A, Chintagumpala M, Ashley D, Kellie S, Yun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Boyett JM, Wallace D, Gilbertson RJ (2006) Risk-adapted craniospinal radiotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicenter trial. Lancet Oncol 7:813–820
Johnston DL, Keene D, Bartels U, Carret AS, Crooks B, Eisenstat DD, Fryer C, Lafay-Cousin L, Larouche V, Moghrabi A, Wilson B, Zelcer S, Silva M, Brossard J, Bouffet E (2009) Medulloblastoma in children under the age of three years: a retrospective Canadian review. J Neurooncol 94:51–56
Bishop AJ, McDonald MW, Chang AL, Esiashvili N (2012) Infant brain tumors: incidence, survival and the role of radiation based on surveillance, epidemiology and end result (SEER) data. Int J Radiat Oncol Biol Phys 82:341–347
Ashley D, Merchant TE, Strother D, Zhou T, Duffner P, Burger PC, Miller DC, Lyon N, Bonner MJ, Msall M, Buxton A, Geyer R, Kun LE, Coleman L, Pollack IF (2012) Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: Children’s Oncology Group study P9934. J Clin Oncol 30:3181–3186
Von Bueren AO, von Hoff K, Pietsch T, Gerber NU, Warmuth-Metz M, Deinlein F, Zwiener I, Faldum A, Fleischhack G, Benesch M, Krauss J, Kuehl J, Kortmann RD, Rutkowski S (2011) Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro-Oncology 13:669–679
De Souza RM, Jones BR, Lowis SP, Kurian KM (2014) Pediatric medulloblastoma—update on molecular classification driving targeted therapies. Front Oncol 4:176
Conflict of interest
The authors have no conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Johnston, D.L., Keene, D., Kostova, M. et al. Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive. J Neurooncol 124, 247–253 (2015). https://doi.org/10.1007/s11060-015-1831-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-015-1831-0